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Abstract
Background: Evidence-based patient information (EBPI) has been recognised as important tool for informed
choice in particular in the matter of preventive options. An objective, on the best scientific evidence-based
consumer information about subthreshold elevated blood glucose levels (impaired fasting glucose and impaired
glucose tolerance) and primary prevention of diabetes, is not available yet. Thus we developed a web-based EBPI
and aim to evaluate its effects on informed decision making in people 50 years or older.
Methods/Design: We conduct a web-based randomised-controlled trial to evaluate the effect of information
about elevated blood glucose levels and diabetes primary prevention on five specific outcomes: (i) knowledge of
elevated blood glucose level-related issues (primary outcome); (ii) attitudes to a metabolic testing; (iii) intention to
undergo a metabolic testing; (iv) decision conflict; (v) satisfaction with the information. The intervention group
receives a specially developed EBPI about subthreshold elevated blood glucose levels and diabetes primary
prevention, the control group information about this topic, available in the internet.
The study population consists of people between 50 and 69 years of age without known diabetes. Participants will
be recruited via the internet page of the cooperating health insurance company, Techniker Krankenkasse (TK), and
the internet page of the German Diabetes Centre. Outcomes will be measured through online questionnaires. We
expect better informed participants in the intervention group.
Discussion: The design of this study may be a prototype for other web-based prevention information and their
evaluation.
Trial registration: Current Controlled Trial: ISRCTN22060616.
Background
Options for primary prevention require very careful con-
sideration and value-neutral information, because a pre-
viously healthy population is defined as needing
treatment and considered over a long period of preven-
tive measures. Primary prevention of diabetes is much
debated. Evidence-based patient information (EBPI) tai-
lored to their needs, should be available for all consu-
mers, because it is essential for informed choice and
shared decision-making in the matter of screening pro-
cedures and preventive or treatment options [1-3].
Relating to early diagnosis, evidence-based patient infor-
mation should enable the estimation of the personal risk
and therefore giving a basis to the patient to estimate
potential and consequences. EBPI on subthreshold ele-
vated blood glucose levels (impaired fasting glucose,
IFG, and impaired glucose tolerance, IGT) is not avail-
able yet. Since the concept of prediabetes is discussed
intensively and identified of high relevance to public
health we developed a web-based EBPI [4]. The develop-
ment of the EBPI followed the accepted steps of EBPI
development [3]: 1) systematic literature search
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of relevant publications using predefined inclusion and
exclusion criteria, 3) critical appraisal of the literature,
4) translation of the main results into information rele-
vant for consumers using risk communication techni-
ques, 5) and careful piloting of the EBPI within focus
groups.
Subthreshold elevated blood glucose levels are charac-
terised as impaired glucose tolerance (IGT) or impaired
fasting glucose (IFG). These are risk factors for type 2
diabetes mellitus [5]. IFG and/or IGT were found in a
frequency up to 25% in the older population in Ger-
many [6]. The standardised (age and sex) incidence
rates of Type 2 diabetes in this population (95% CI) per
1,000 person-years were 15.5 (12.6-19.1) in the total
cohort, 20.2 (15.6-26.1) in men and 11.3 (7.9-16.1) in
women [7]. Hence, a screening for elevated blood glu-
cose levels might allow identifying a target group for
primary prevention of diabetes mellitus. Randomised
controlled trials in Finland and the USA suggest a
reduction of diabetes mellitus diagnoses in people with
subthreshold elevated blood glucose levels through life-
style-interventions [8,9].
In this study, we aim to optimise the information on
elevated blood glucose levels and diabetes primary pre-
vention provided for people 50 years or older by a care-
fully developed and piloted EBPI. We aim to investigate
if an EBPI could improve the decision making process.
Methods/Design
Development of the evidence-based patient information
The development of the EBPI followed the accepted
steps of EBPI development [3]: 1) systematic literature
search performed by two researchers (AS and GM), 2)
selection of relevant publications using predefined inclu-
sion and exclusion criteria, 3) critical appraisal of the lit-
erature, 4) translation of the main results into
information relevant for consumers using risk commu-
nication techniques, 5) careful piloting of the EBPI
within 41 participants in several focus groups.
Study design and setting
Pilot testing covered feasibility and acceptability testing
of the instruments and procedures. The testing of the
instruments took place via focus groups (15 partici-
pants) and via postal evaluation (31 participants). Proce-
dures were tested online in several passes, primarily
among employees of the participating project partners.
In October 2009, the information has been made avail-
able to the study population via web-based assess. We
invite visitors of the internet pages of the cooperating
health insurance company, Techniker Krankenkasse
(TK), and the German Diabetes Centre to take part in
the study. Incentives such as books and wellness funds
are drawn in order to increase the response rate.
Individuals who agree to participate and give their
informed consent are randomly assigned to the experi-
mental (evidence-based consumer information) or the
control group (standard information). Randomisation is
stratified according to sex and age.
Intervention
Participants are presented either internet-based EBPI
(experimental group) or standard information (control
group). A widely used brochure published in the inter-
net and two articles of popular websites are used as
standard information on subthreshold elevated blood
glucose levels or diabetes [10-12]. The standard infor-
mation offers information about prevention, early detec-
tion, sequelae and treatment of diabetes mellitus. The
EBPI summarises the existing knowledge from the scien-
tific literature on the topic.
Study population: Inclusion and exclusion criteria
Visitors of the above mentioned two internet pages are
invited to participate and to answer online question-
naires when they are aged 50 to 69 years and without
known diabetes. Participants who mention to have a
diagnosis of type 2-diabetes mellitus are excluded before
the statistical evaluation.
Study execution
Participants obtain the internet information (EBPI or
standard, respectively) on blood glucose disorders, meta-
bolic testing (diabetes-testing) and prevention strategies.
The survey is carried out at three points in time (T0/
T1, T2), with the first two times during one visit to the
website. T0 or T1 is the questioning before or after
reading the information, so that the gain of knowledge
and a characterisation of later drop-outs is ascertainable.
T2 is the online follow-up survey two weeks after the
first online session (see Figure 1).
The variables of the T0-survey and some user beha-
viour, e.g. point where participants quit the study, will
be recorded for later drop-out-analysis.
Outcomes
In this study five outcomes will be measured: (i) knowl-
edge of elevated blood glucose level-related issues - the
main outcome of the study; (ii) attitudes to a metabolic
testing; (iii) intention to undergo a metabolic testing;
(iv) decisional conflict; (v) satisfaction with the informa-
tion. All outcomes will be assessed using self-completed
online questionnaires. All translated or newly developed
instruments have been carefully piloted based on
accepted focus group procedures [13-17].
The main outcome ‘knowledge’ will be assessed using
an eight-item multiple-choice-scale about the benefits
and risks of blood glucose screening. Because there is
no German version of a validated instrument on this
topic available, we developed an own questionnaire
based on Anglo-American and German instruments
[18-23]. The questionnaire is adapted to the EBPI and
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choice about blood glucose testing.
Attitudes to a metabolic testing (screening test about
elevated blood glucose) are determined by a four-item
scale [24].
Intention to undergo metabolic testing within the next
12 months: This will be assessed using a single item
question (translated into German) with a five point
response scale, according to Gattellari et al 2003 [25].
Decisional conflict is measured using the decisional
conflict scale (DCS). This is a 16 item scale which elicits
uncertainty in choosing among health-related alterna-
tives, contributing factors to uncertainty and the per-
ceived effective decision making. It discriminates
between subjects who make and who delay decisions.
The five-point Likert scale is anchored by “strongly
agree” and “strongly disagree”. The DCS has met accep-
table standards of reliability and validity [26,27]. A Ger-
man authorised translation which has been already used
in comparable studies, is available [28]. Because the
measure is conducted before a decision is made, we set
aside the four items which target the situation after the
decision. This approach is similar to an earlier evalua-
tion [29].
Satisfaction with the information and the information
available is surveyed each with an according question
using school grades.
Further variables
Personal data (age, sex, socio-economic variables, life
satisfaction) are also assessed. A short instrument has
been developed on the basis of recommendations of the
German Society of Epidemiology [30]. To assess life
satisfaction, a single question from the socio-economic
panel is applied [31]. A scale in the form of a 10 rung
ladder is used to measure subjective social status [32].
Furthermore, subjects are asked for their medical his-
tory, in particular, diabetes mellitus. Participants are
also asked if they already passed a blood glucose test.
Randomisation
Randomisation takes place immediately before presenta-
tion of the information, deposited on a random number
generator. To gain a balanced distribution of the study
population characteristics, a stratified block randomisa-
tion is conducted (4 strata defined by women/men and
40-49 years/50 years and older, 1:1 randomisation
between intervention and controls within each stratum
using blocks of size 10).
Crossover between the study groups is not possible,
because the IP-addresses of the participants are identi-
fied by the system.
Statistical analysis
Data of all randomised participants excluding those with
self-documented diabetes will be evaluated. The primary
analysis will be performed on the study population of
T1 compliers with non-missing primary outcome of
knowledge. The secondary analysis set will be the subset
of compliers of T1 and T2.
The persons who have prematurely terminated the
study without completely documented knowledge out-
come of T1 will be compared with the study population
on the basis of the parameters which are assessed before
randomisation (age, sex, education, life satisfaction, and
pre-study knowledge about elevated blood glucose),
using appropriate statistical tests (chi-square test, Fish-
er’s exact test, t-test or Wilcoxon test). Furthermore, the
subgroup of the T1/T2 compliers will be compared with
the study population of T1 compliers in a similar
manner.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*about elevated blood glucose levels and diabetes primary prevention 
T2 (follow-up) 
Attitude 
Intention to uptake metabolic 
testing 
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Figure 1 Progress of intervention.
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control group on an ‘intention to treat’ basis. For the
description of the population in terms of relevant basic
parameters - according to distribution - frequency
tables, prevalences with 95% confidence intervals or
mean values with standard deviations will be calculated.
Scores on knowledge and quality of the decision and
satisfaction will be evaluated by average scale scores
with standard deviations and percentiles. The estimates
will be carried out in the intervention and control group
respectively in total and stratified for relevant sub-
groups, e.g. age (40-49 years or older) and sex. To test
any effects of the intervention, statistical comparisons
will be performed - according to distribution - by chi-
square or Fisher’s exact test, t-test or Wilcoxon’sr a n k
sum test. The tests for each target variable is to be
defined before the evaluation.
The primary outcome is an ordinal score with values
0-8. The distributions between intervention and control
group will be compared primarily by Wilcoxon’sr a n k
sum test. In a secondary analysis the outcome “good
knowledge” is defined by dichotomisation of the ordinal
knowledge score using a predefined cut point of 5 (≥ 5
versus <5). Intervention and control group will be com-
pared by chi-square test.
The association between this primary outcome and
predictors is estimated using multiple ordinal logistic
regression models. A continuation-ratio logit model will
be fitted [33]. To simplify the interpretation of the
results the scale of the knowledge score will be reduced
to 3 ordered values by the predefined classes 0-2, 3-5
and 6-8. The predictors are first examined by univariate
models. Then, multiple models considering age, sex,
socio-economic variables and participation in a blood
glucose test will be discussed.
Then, multiple models considering age, sex, socio-eco-
nomic variables, participation in a blood glucose test
and pre-study knowledge about elevated blood glucose
will be discussed. A final multiple regression model will
be fitted.
A secondary analysis will be performed on the subpo-
pulation of participants at T1 and T2 considering the
ordinal outcomes “attitude” and “intention to undergo
uptake a metabolic testing”. These variables will be
described non-parametrically and control and interven-
tion group will be compared using Wilcoxon’s rank sum
test.
Sample size and statistical power
The main outcome is knowledge, on which the sample
size calculation is based. The knowledge questionnaire
includes 8 items. Each item is rated right/wrong or not
completed, which will be awarded with 0 or 1 point.
Result of the knowledge test therefore cover 0-8 points.
The statistical power using primarily Wilcoxon’sr a n k
sum test was estimated roughly using the power calcula-
tion of the corresponding t-test assuming approximate
normal distribution. Nothing was known about the dis-
tribution of the ordinal outcome. A sample size of 527
evaluable participants per group will be enough to
d e t e c tad i f f e r e n c eo f0 . 2 0s of the expected values
between intervention and control group by 90% power
using a significance level of a =5 %a n da2 - s i d e dt e s t
(s = common standard deviation on both groups). In
view of the planned multiple regression analysis and the
secondary analysis of the ordinal outcome a relatively
large sample size was planned.
Ethical considerations
Participation is based on informed consent in accor-
dance with the Declaration of Helsinki. All participants
give their informed consent for participation in the
study in an internet formulary.
The data security official of the German Diabetes Cen-
tre approved the study on 16/01/2008 and the amended
protocol on 02/08/2009.
The Ethics Committee of the University of Düsseldorf
approved the design of the study on 28/02/2008 and the
amended protocol on 07/08/2009, reference number:
3020.
Discussion
Diabetes prevention is currently being widely discussed.
An evidence-based processing of the available evidence
is therefore of great relevance and can be widely used.
In health services research patient-oriented questions
and information transfer, information presentation and
evaluation are increasingly playing a central role [34].
Thus, a thorough review of the project outcomes is of
great interest, also from a scientific perspective.
Health information is increasingly available on the
internet. An online information is therefore of major
practical importance [35]. With the initial establishment
of an evidence-based information to a “pre-diabetic”
situation and primary prevention of diabetes and its use
as an online-based evidence-based information, the pro-
ject is also from a international scientific point of view a
methodological challenge and markedly innovative.
Web-based systems are not likely to achieve representa-
tive results for the population. Potential advantages lie
in new opportunities for evaluation and possibly in a
high cost effectiveness of the method. The design of this
study may act as prototype for other web-based preven-
tion information and their evaluation. Concerning
potential long-term consequences of the intervention,
no statements are possible at this time.
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